We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · November 19, 2018

Palbociclib Plus an Aromatase Inhibitor or Fulvestrant for HR+/HER2− Advanced/Metastatic Breast Cancer

The Breast


Additional Info

Disclosure statements are available on the authors' profiles:

The Breast
Treatment Patterns and Clinical Outcomes Among Patients Receiving Palbociclib in Combination With an Aromatase Inhibitor or Fulvestrant for HR+/HER2-Negative Advanced/Metastatic Breast Cancer in Real-World Settings in the US: Results From the IRIS Study
Breast 2019 Feb 01;43(xx)22-27, G Taylor-Stokes, D Mitra, J Waller, K Gibson, G Milligan, S Iyer

Further Reading